For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Vesugen (Lys-Glu-Asp, KED) is a synthetic tripeptide derived from vascular wall protein sequences, developed by Professor Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is the most clinically studied Khavinson bioregulator to cross into human territory: small Russian observational studies in atherosclerosis patients, post-surgical lower limb ischemia cases, and vasculogenic erectile dysfunction report meaningful improvements in vascular endpoints. The mechanistic work, including Ki-67 gene promoter docking, SIRT1 upregulation, and endothelin-1 normalization in endothelial cultures, is more developed than most Khavinson compounds. None of the human studies were randomized, blinded, or placebo-controlled, and all originate from a single research institution.
The complete Vesugen profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use